Vor Biopharma Announces Board and Executive Changes
Ticker: VOR · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Vor Bio's board is shaking up, with new directors and exec comp changes filed today.
AI Summary
Vor Biopharma Inc. announced on November 2, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial stability.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- November 02, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39979 (commission_file_number) — SEC File Number
- 81-1591163 (ein) — IRS Employer Identification No.
- 500 Boylston Street, Suite 1350 (address) — Principal Executive Offices
- Boston (city) — Principal Executive Offices City
- Massachusetts (state) — Principal Executive Offices State
- 02116 (zip_code) — Principal Executive Offices Zip Code
- 617 655-6580 (phone_number) — Registrant's Telephone Number
FAQ
What specific items are being reported in this Form 8-K?
This Form 8-K reports on the departure of directors or certain officers, the election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on November 02, 2025.
What is Vor Biopharma Inc.'s state of incorporation?
Vor Biopharma Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116.
What is the SIC code for Vor Biopharma Inc.?
The Standard Industrial Classification (SIC) code for Vor Biopharma Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-11-03 08:02:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
Filing Documents
- vor-20251102.htm (8-K) — 47KB
- vor-ex99_1.htm (EX-99.1) — 16KB
- img246614764_0.jpg (GRAPHIC) — 95KB
- 0001193125-25-261723.txt ( ) — 303KB
- vor-20251102.xsd (EX-101.SCH) — 24KB
- vor-20251102_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 3, 2025, the Company issued a press release announcing the appointment of Dr. Jeremy Sokolove as Chief Medical Officer, a copy of which is furnished as Exhibit 99.1 to this report and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: November 3, 2025 By: /s/ Jean-Paul Kress Name: Jean-Paul Kress Title: Chief Executive Officer